RATIONALE FOR THE CHOICE OF ANTIHYPERTENSIVE THERAPY: RESULTS OF THE PRESTIGE REGIONAL STUDY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Evidence is provided for the incorporation of Prestarium A in a dose of 10 mg into the antihypertensive therapy of uncontrolled arterial hypertension (AH) to achieve goal blood pressure (BP) and to improve quality of life (QL) in metabolic neutrality. The use of Prestarium A 10 mg in the combination therapy of uncontrolled AH could achieve goal BP in 80% of the patients following 6-month therapy; at the same time there was a better daily BP profile manifesting as reductions in time index and morning BP elevation rate and as an increase in its nocturnal lowering. The drug was recorded to have a favorable effect on some lipid metabolic parameters and glomerular filtration rate. During the therapy, there were positive QL changes estimated using the visual analog scale.

全文:

受限制的访问

作者简介

E. Solyanlk

Vladivostok State Medical University, Far Eastern Medical Center

Email: yes.vlad@yandex.ru

I. Borodina

Vladivostok State Medical University, Far Eastern Medical Center

Email: yes.vlad@yandex.ru

Zh. Gushchina

Vladivostok State Medical University, Far Eastern Medical Center

Email: yes.vlad@yandex.ru

M. Egorova

Vladivostok State Medical University, Far Eastern Medical Center

Email: yes.vlad@yandex.ru

T. Koroleva

Vladivostok State Medical University, Far Eastern Medical Center

Email: yes.vlad@yandex.ru

L. Ryzhova

Vladivostok State Medical University, Far Eastern Medical Center

Email: yes.vlad@yandex.ru

参考

  1. Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л. и др. Анализ фармакотерапии по результатам исследования ПИФАГОР III // Фарматека. - 2010; 13: 87-95.
  2. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации // Рос. кардиол. журн. - 2006; 4: 45-50.
  3. Карпов Ю.А. Новые рекомендации по артериальной гипертензии РМОАГ/ ВНОК 2010 г.: вопросы комбинированной терапии // РМЖ. - 2010; 18 (22): 1290-7.
  4. Donnan G., Davis S. Angiotensin receptor and stroke therapy. It is all about the blood pressure // Stroke. - 2009; 40: 3163.
  5. Карпов Ю.А., Деев А.Д. от имени участников исследования ПРИВИЛЕГИЯ - Престариум в лечении артериальной гипертонии: эффективность и безопасность в сравнении с эналаприлом // Кардиология. - 2007; 7: 35-40.
  6. Danlof B., Sever P., Pouter N. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipin adding perindopril as required versus atenolol adding bendroflumehiaside as required, in the Anglo - Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial // Lancet. - 2005; 366: 395-906.
  7. Sever P., Danlof B., Pouter N. et al. on behalf of the ASCOT Steering Committee Members. Potential synergy between lipid - lowering and blood-pressure in the Anglo - Scandinavian Cardiac Outcomes Trial // Eur. Heart J. -2006; 27: 2982-8.
  8. PROGRESS Collaborative Group // Lancet. - 2001; 358: 1033-41.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##